## NUE: Nucor Corporation - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($149.46)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 1, Bearish: 2)

**1. Nucor sees lower Q4 earnings sequentially across all segments**
- Source: Steel Market Update | 20251217T175625 | Bearish | Relevance: 100%
- Nucor anticipates lower sequential earnings in Q4 2025 across all three operating segments due to seasonal effects and fewer shipping days, despite expecting higher earnings compared to Q4 2024. The steelmaker projects earnings per diluted share in the range of $1.65 to $1.75. Looking to 2026, Nucor is encouraged by materially higher backlogs driven by momentum in construction market segments like energy, infrastructure, data centers, and manufacturing.

**2. Is It Too Late To Consider Nucor After Its 40% Surge In 2025?**
- Source: Yahoo Finance | 20251218T021744 | Bullish | Relevance: 100%
- Nucor (NUE) has surged 40.4% year to date in 2025, leading investors to question its current valuation. Despite this run, a Simply Wall St analysis suggests Nucor is still undervalued, with a Discounted Cash Flow model indicating it is 71.1% below its intrinsic value. The article also highlights Nucor's P/E ratio which is below industry and peer averages, further supporting an undervalued assessment.

**3. Nucor Faces Seasonal Headwinds In Q4, Yet Order Backlogs Signal 2026 Recovery**
- Source: Benzinga | 20251217T150809 | Neutral | Relevance: 100%
- Nucor (NYSE: NUE) shares are trading lower after the company issued fourth-quarter EPS guidance below analyst estimates, projecting $1.65â€“$1.75 compared to the $2.18 consensus. The company cited seasonal pressures and fewer shipping days for the expected decline across all three operating segments, but noted improving order backlogs heading into 2026. Nucor expects gradual improvements in business conditions for 2026, supported by favorable monetary, tax, and trade policies.

**4. Nucor expects Q4 earnings to decline amid seasonal effects**
- Source: Investing.com | 20251217T130840 | Somewhat-Bearish | Relevance: 100%
- Nucor Corporation anticipates a decline in its fourth-quarter 2025 earnings, projecting $1.65 to $1.75 per diluted share, down from $2.63 in Q3, attributing this to seasonal factors and fewer shipping days. Despite the expected Q4 dip across all operating segments, the company maintains an optimistic outlook for 2026, citing significantly higher backlogs. Nucor has also been active in share repurchases and recently increased its quarterly dividend, while leadership changes are expected in early 2026.

**5. Nucor, Steel Dynamics Warn of Profit Shortfalls**
- Source: The Wall Street Journal | 20251217T143003 | Bearish | Relevance: 99%
- Steelmakers Nucor and Steel Dynamics have issued warnings that their fourth-quarter earnings will fall significantly short of Wall Street's expectations. Nucor anticipates earnings of $1.65 to $1.75 per share, below the $2.16 analyst forecast, while Steel Dynamics expects $1.65 to $1.69 per share, missing the $2.25 estimate. Both companies attribute the decline to seasonal effects and fewer shipping days.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Wells Fargo | $176 | $178 | -1% |
| 2025-12-15 | Wells Fargo | $178 | $167 | +7% |
| 2025-12-10 | Jefferies | $190 | $170 | +12% |
| 2025-12-05 | JP Morgan | $200 | $175 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Wells Fargo | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-10 | Jefferies | main | Buy |
| 2025-12-05 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($2.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (-3.1%)
- State Farm Mutual Au: 10.6% (-0.7%)
- Blackrock Inc.: 8.1% (-3.6%)
- State Street Corpora: 5.3% (-2.7%)
- Berkshire Hathaway, : 2.8% (-3.1%)

### Key Risks

1. High beta (1.86) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_10 falling (-4.2% 5d) with bearish MACD, trend may be turning.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.75 indicates undervaluation relative to growth. Forward P/E 13.6x attractive for 45% earnings growth. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (3 raises, avg +11%). Insider selling cluster ($2.3M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.1B |
| Beta | 1.86 |
| 52W Range | $97.59 - $168.07 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.75 |
| Forward P/E | 13.6 |
| Current P/E | 19.7 |
| YoY Growth | 45.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.0% to -1.1% (-4.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Underperforming sector by 3.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-0.78), momentum weakening. RSI neutral at 51. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.11% (CS: 26) | Neutral |
| RSI_14 | 51.4 | Neutral |
| MACD Histogram | -0.78 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 1.054x | Above |
| vs SMA200 | 1.172x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $157.78
- **Stop Loss:** $149.46 (5.3% risk)
- **Target:** $166.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 137
- **Position Value:** $21,615.86
- **Portfolio %:** 21.62%
- **Risk Dollars:** $1,140.00
- **Risk Per Trade:** 1.14%
- **Modifiers:** L1 95% | L2 120% | Combined 1.14x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-26 (Est: $2.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.16 | $2.63 | +22.0% |
| 2025Q2 | $2.61 | $2.60 | -0.6% |
| 2025Q1 | $0.61 | $0.67 | +9.8% |
| 2024Q4 | $0.64 | $1.22 | +90.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*